Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox in Anemic MDS Patients with Iron Overload
NCT02943668Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Mar 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of deferasirox in myelodysplastic syndrome (MDS), sponsored by Fred Hutchinson Cancer Center. Started Mar 2017; status: terminated.
02
Drugs
deferasirox
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02943668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02943668.